Nasonex (Mometasone Furoate)

Mometasone furoate, the corticosteroid in Nasonex, binds to glucocorticoid receptors in nasal tissues. This binding suppresses the production of inflammatory cytokines and mediators, leading to decreased swelling and irritation of the nasal mucosa.

The exact dosing regimen for Nasonex is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Patients should follow the prescriber’s instructions and the product label.

Safety data for Nasonex in pregnancy are limited, so it should only be used if the potential benefit justifies any potential risk. While breastfeeding, the decision to continue treatment should be made after discussing possible risks and benefits with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasonex (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic absorption profile, similar to other agents such as fluticasone propionate. Clinical choice often depends on physician preference, patient response, dosing convenience and formulary availability.

Nasonex should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct heat, and avoid freezing the product.

Nasonex is delivered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press down to release one spray while breathing in gently. The process is repeated in the other nostril as directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, vision changes (e.g., cataracts, glaucoma), and adrenal suppression with prolonged high‑dose use. Patients should seek immediate medical attention if they notice any of these symptoms.

Nasonex is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated infections of the nasal passages or recent nasal surgery unless directed by a physician.